rhC1INH cuts attack frequency in hereditary angioedema

November 9, 2012
rhC1INH cuts attack frequency in hereditary angioedema
For patients with hereditary angioedema, weekly administration of recombinant C1INH is well tolerated and is associated with a reduction in attack frequency, according to a study published online Nov. 5 in Allergy.

(HealthDay)—For patients with hereditary angioedema (HAE), weekly administration of recombinant C1INH (rhC1INH) is well tolerated and is associated with a reduction in attack frequency, according to a study published online Nov. 5 in Allergy.

Avner Reshef, M.D., from the Chaim Sheba Medical Center in Tel Hashomer, Israel, and colleagues examined the safety and prophylactic effect of weekly administration of rhC1INH (50 U/kg body weight) in a study involving 25 patients with a history of HAE attacks occurring at least every two weeks. Following a two-week run-in period, patients received rhC1INH administration every week for eight weeks, and were followed for an additional six weeks.

The researchers found that, over the past two years, participants reported attacks at a rate of 0.9/week. During the treatment period, the mean attack rate was 0.4/week. In 13 patients, 30 treatment-emergent mild-to-moderate adverse events were reported. Twenty-five days after the last study drug administration, one patient died from a laryngeal attack. , , and anxiety were reported as the only possible drug-related adverse events in one patient and hypotension was reported in another. No allergic adverse events were reported.

"In summary, weekly administration of 50 U/kg rhC1INH appeared to reduce the frequency of HAE attacks and was generally safe and well tolerated," the authors write. "These encouraging findings warrant further investigation of the clinical value of with rhC1INH."

Several authors disclosed financial ties to the .

Explore further: New drug shown safe, effective in treating hereditary angioedema

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Belimumab deemed safe for long-term lupus treatment

June 19, 2012

(HealthDay) -- For patients with systemic lupus erythematosus (SLE), long-term belimumab therapy combined with standard therapy is well tolerated, according to a study published online June 5 in Arthritis & Rheumatism.

Low-dose duloxetine deemed safe for urinary incontinence

July 27, 2012

(HealthDay) -- Duloxetine appears safe for the routine clinical care of women with stress urinary incontinence (SUI), according to a study published online July 23 in the British Journal of Clinical Pharmacology.

Metastatic melanoma responds to first-line interleukin-21

August 23, 2012

(HealthDay)—In the first-line treatment of metastatic melanoma, interleukin-21 (IL-21) shows an overall response rate (ORR) of 22.5 percent and warrants further study, according to research published online Aug. 20 in the ...

Recommended for you

Acetaminophen does not aggravate children's asthma

August 17, 2016

Contrary to earlier reports, giving acetaminophen (Tylenol, etc.) for pain and fever does not worsen asthma in young children with the condition, concludes a randomized trial in the August 18 New England Journal of Medicine.

Big step towards cure for lifelong viral infections

August 3, 2016

New research has taken us a step closer to finding a cure for human immunodeficiency virus (HIV), as well as other infections including the glandular fever virus, which is associated with the development of lymphoma. Some ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.